Boosted production of antibodies that neutralized different SARS-CoV-2 variants in a COVID-19 convalescent following messenger RNA vaccination - a case study
Vaccinated convalescents do not develop severe COVID-19 after infection with new SARS-CoV-2 variants. We questioned how messenger RNA (mRNA) vaccination of convalescents provides protection from emerging virus variants. From the cohort of 71 convalescent plasma donors, we identified a patient who de...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-12-01
|
| Series: | International Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971223007488 |
| _version_ | 1797435808921157632 |
|---|---|
| author | Erlend Ravlo Aleksandr Ianevski Eirin Starheim Wei Wang Ping Ji Hilde Lysvand Teemu Smura Gaily Kivi Maia-Liisa Voolaid Kati Plaan Mart Ustav Mart Ustav, Jr. Eva Zusinaite Tanel Tenson Reet Kurg Valentyn Oksenych Kirsti Walstad Svein Arne Nordbø Mari Kaarbø Karin Ernits Magnar Bjørås Denis E. Kainov Mona Høysæter Fenstad |
| author_facet | Erlend Ravlo Aleksandr Ianevski Eirin Starheim Wei Wang Ping Ji Hilde Lysvand Teemu Smura Gaily Kivi Maia-Liisa Voolaid Kati Plaan Mart Ustav Mart Ustav, Jr. Eva Zusinaite Tanel Tenson Reet Kurg Valentyn Oksenych Kirsti Walstad Svein Arne Nordbø Mari Kaarbø Karin Ernits Magnar Bjørås Denis E. Kainov Mona Høysæter Fenstad |
| author_sort | Erlend Ravlo |
| collection | DOAJ |
| description | Vaccinated convalescents do not develop severe COVID-19 after infection with new SARS-CoV-2 variants. We questioned how messenger RNA (mRNA) vaccination of convalescents provides protection from emerging virus variants. From the cohort of 71 convalescent plasma donors, we identified a patient who developed immune response to infection with SARS-CoV-2 variant of 20A clade and who subsequently received mRNA vaccine encoding spike (S) protein of strain of 19A clade. We showed that vaccination increased the production of immune cells and anti-S antibodies in the serum. Serum antibodies neutralized not only 19A and 20A, but also 20B, 20H, 21J, and 21K virus variants. One of the serum antibodies (100F8) completely neutralized 20A, 21J, and partially 21K strains. 100F8 was structurally similar to published Ab188 antibody, which recognized non-conserved epitope on the S protein. We proposed that 100F8 and other serum antibodies of the patient which recognized non- and conserved epitopes of the S protein, could have additive or synergistic effects to neutralize various virus variants. Thus, mRNA vaccination could be beneficial for convalescents because it boosts production of neutralizing antibodies with broad-spectrum activity. |
| first_indexed | 2024-03-09T10:53:28Z |
| format | Article |
| id | doaj.art-8098c1ee0a8344b78dfaa169d2000625 |
| institution | Directory Open Access Journal |
| issn | 1201-9712 |
| language | English |
| last_indexed | 2024-03-09T10:53:28Z |
| publishDate | 2023-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj.art-8098c1ee0a8344b78dfaa169d20006252023-12-01T05:00:54ZengElsevierInternational Journal of Infectious Diseases1201-97122023-12-011377578Boosted production of antibodies that neutralized different SARS-CoV-2 variants in a COVID-19 convalescent following messenger RNA vaccination - a case studyErlend Ravlo0Aleksandr Ianevski1Eirin Starheim2Wei Wang3Ping Ji4Hilde Lysvand5Teemu Smura6Gaily Kivi7Maia-Liisa Voolaid8Kati Plaan9Mart Ustav10Mart Ustav, Jr.11Eva Zusinaite12Tanel Tenson13Reet Kurg14Valentyn Oksenych15Kirsti Walstad16Svein Arne Nordbø17Mari Kaarbø18Karin Ernits19Magnar Bjørås20Denis E. Kainov21Mona Høysæter Fenstad22Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, Trondheim, NorwayDepartment of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, Trondheim, NorwayDepartment of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, Trondheim, NorwayDepartment of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, Trondheim, NorwayDepartment of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, Trondheim, NorwayDepartment of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, Trondheim, NorwayDepartment of Virology, University of Helsinki, Helsinki, Finland; HUS Diagnostic Center, Clinical Microbiology, Helsinki University Hospital, University of Helsinki, Helsinki, FinlandIcosagen Cell Factory OÜ, Tartu, EstoniaIcosagen Cell Factory OÜ, Tartu, EstoniaIcosagen Cell Factory OÜ, Tartu, EstoniaIcosagen Cell Factory OÜ, Tartu, EstoniaIcosagen Cell Factory OÜ, Tartu, EstoniaInstitute of Technology, University of Tartu, Tartu, EstoniaInstitute of Technology, University of Tartu, Tartu, EstoniaInstitute of Technology, University of Tartu, Tartu, EstoniaBroegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, NorwayDepartment of Immunology and Transfusion Medicine, St. Olavs Hospital, Trondheim, NorwayDepartment of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, Trondheim, Norway; Department of Immunology and Transfusion Medicine, St. Olavs Hospital, Trondheim, NorwayDepartment of Microbiology, Oslo University Hospital and University of Oslo, Oslo, NorwayDepartment of Experimental Medicine, University of Lund, Lund, SwedenDepartment of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, Trondheim, Norway; Department of Microbiology, Oslo University Hospital and University of Oslo, Oslo, Norway; Centre for Embryology and Healthy Development, University of Oslo and Oslo University Hospital, Oslo, NorwayDepartment of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, Trondheim, Norway; Institute of Technology, University of Tartu, Tartu, Estonia; Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland; Corresponding author: Tel.: +(47) 73598474.Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, Trondheim, Norway; Department of Immunology and Transfusion Medicine, St. Olavs Hospital, Trondheim, NorwayVaccinated convalescents do not develop severe COVID-19 after infection with new SARS-CoV-2 variants. We questioned how messenger RNA (mRNA) vaccination of convalescents provides protection from emerging virus variants. From the cohort of 71 convalescent plasma donors, we identified a patient who developed immune response to infection with SARS-CoV-2 variant of 20A clade and who subsequently received mRNA vaccine encoding spike (S) protein of strain of 19A clade. We showed that vaccination increased the production of immune cells and anti-S antibodies in the serum. Serum antibodies neutralized not only 19A and 20A, but also 20B, 20H, 21J, and 21K virus variants. One of the serum antibodies (100F8) completely neutralized 20A, 21J, and partially 21K strains. 100F8 was structurally similar to published Ab188 antibody, which recognized non-conserved epitope on the S protein. We proposed that 100F8 and other serum antibodies of the patient which recognized non- and conserved epitopes of the S protein, could have additive or synergistic effects to neutralize various virus variants. Thus, mRNA vaccination could be beneficial for convalescents because it boosts production of neutralizing antibodies with broad-spectrum activity.http://www.sciencedirect.com/science/article/pii/S1201971223007488SARS-CoV-2COVID-19mRNA vaccinationImmune responseNeutralizing antibody |
| spellingShingle | Erlend Ravlo Aleksandr Ianevski Eirin Starheim Wei Wang Ping Ji Hilde Lysvand Teemu Smura Gaily Kivi Maia-Liisa Voolaid Kati Plaan Mart Ustav Mart Ustav, Jr. Eva Zusinaite Tanel Tenson Reet Kurg Valentyn Oksenych Kirsti Walstad Svein Arne Nordbø Mari Kaarbø Karin Ernits Magnar Bjørås Denis E. Kainov Mona Høysæter Fenstad Boosted production of antibodies that neutralized different SARS-CoV-2 variants in a COVID-19 convalescent following messenger RNA vaccination - a case study International Journal of Infectious Diseases SARS-CoV-2 COVID-19 mRNA vaccination Immune response Neutralizing antibody |
| title | Boosted production of antibodies that neutralized different SARS-CoV-2 variants in a COVID-19 convalescent following messenger RNA vaccination - a case study |
| title_full | Boosted production of antibodies that neutralized different SARS-CoV-2 variants in a COVID-19 convalescent following messenger RNA vaccination - a case study |
| title_fullStr | Boosted production of antibodies that neutralized different SARS-CoV-2 variants in a COVID-19 convalescent following messenger RNA vaccination - a case study |
| title_full_unstemmed | Boosted production of antibodies that neutralized different SARS-CoV-2 variants in a COVID-19 convalescent following messenger RNA vaccination - a case study |
| title_short | Boosted production of antibodies that neutralized different SARS-CoV-2 variants in a COVID-19 convalescent following messenger RNA vaccination - a case study |
| title_sort | boosted production of antibodies that neutralized different sars cov 2 variants in a covid 19 convalescent following messenger rna vaccination a case study |
| topic | SARS-CoV-2 COVID-19 mRNA vaccination Immune response Neutralizing antibody |
| url | http://www.sciencedirect.com/science/article/pii/S1201971223007488 |
| work_keys_str_mv | AT erlendravlo boostedproductionofantibodiesthatneutralizeddifferentsarscov2variantsinacovid19convalescentfollowingmessengerrnavaccinationacasestudy AT aleksandrianevski boostedproductionofantibodiesthatneutralizeddifferentsarscov2variantsinacovid19convalescentfollowingmessengerrnavaccinationacasestudy AT eirinstarheim boostedproductionofantibodiesthatneutralizeddifferentsarscov2variantsinacovid19convalescentfollowingmessengerrnavaccinationacasestudy AT weiwang boostedproductionofantibodiesthatneutralizeddifferentsarscov2variantsinacovid19convalescentfollowingmessengerrnavaccinationacasestudy AT pingji boostedproductionofantibodiesthatneutralizeddifferentsarscov2variantsinacovid19convalescentfollowingmessengerrnavaccinationacasestudy AT hildelysvand boostedproductionofantibodiesthatneutralizeddifferentsarscov2variantsinacovid19convalescentfollowingmessengerrnavaccinationacasestudy AT teemusmura boostedproductionofantibodiesthatneutralizeddifferentsarscov2variantsinacovid19convalescentfollowingmessengerrnavaccinationacasestudy AT gailykivi boostedproductionofantibodiesthatneutralizeddifferentsarscov2variantsinacovid19convalescentfollowingmessengerrnavaccinationacasestudy AT maialiisavoolaid boostedproductionofantibodiesthatneutralizeddifferentsarscov2variantsinacovid19convalescentfollowingmessengerrnavaccinationacasestudy AT katiplaan boostedproductionofantibodiesthatneutralizeddifferentsarscov2variantsinacovid19convalescentfollowingmessengerrnavaccinationacasestudy AT martustav boostedproductionofantibodiesthatneutralizeddifferentsarscov2variantsinacovid19convalescentfollowingmessengerrnavaccinationacasestudy AT martustavjr boostedproductionofantibodiesthatneutralizeddifferentsarscov2variantsinacovid19convalescentfollowingmessengerrnavaccinationacasestudy AT evazusinaite boostedproductionofantibodiesthatneutralizeddifferentsarscov2variantsinacovid19convalescentfollowingmessengerrnavaccinationacasestudy AT taneltenson boostedproductionofantibodiesthatneutralizeddifferentsarscov2variantsinacovid19convalescentfollowingmessengerrnavaccinationacasestudy AT reetkurg boostedproductionofantibodiesthatneutralizeddifferentsarscov2variantsinacovid19convalescentfollowingmessengerrnavaccinationacasestudy AT valentynoksenych boostedproductionofantibodiesthatneutralizeddifferentsarscov2variantsinacovid19convalescentfollowingmessengerrnavaccinationacasestudy AT kirstiwalstad boostedproductionofantibodiesthatneutralizeddifferentsarscov2variantsinacovid19convalescentfollowingmessengerrnavaccinationacasestudy AT sveinarnenordbø boostedproductionofantibodiesthatneutralizeddifferentsarscov2variantsinacovid19convalescentfollowingmessengerrnavaccinationacasestudy AT marikaarbø boostedproductionofantibodiesthatneutralizeddifferentsarscov2variantsinacovid19convalescentfollowingmessengerrnavaccinationacasestudy AT karinernits boostedproductionofantibodiesthatneutralizeddifferentsarscov2variantsinacovid19convalescentfollowingmessengerrnavaccinationacasestudy AT magnarbjøras boostedproductionofantibodiesthatneutralizeddifferentsarscov2variantsinacovid19convalescentfollowingmessengerrnavaccinationacasestudy AT denisekainov boostedproductionofantibodiesthatneutralizeddifferentsarscov2variantsinacovid19convalescentfollowingmessengerrnavaccinationacasestudy AT monahøysæterfenstad boostedproductionofantibodiesthatneutralizeddifferentsarscov2variantsinacovid19convalescentfollowingmessengerrnavaccinationacasestudy |